196 related articles for article (PubMed ID: 31129513)
1. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract][Full Text] [Related]
2. Reversal of the multidrug resistance of human ileocecal adenocarcinoma cells by acetyl-11-keto-β-boswellic acid via downregulation of P-glycoprotein signals.
Xue X; Chen F; Liu A; Sun D; Wu J; Kong F; Luan Y; Qu X; Wang R
Biosci Trends; 2016 Nov; 10(5):392-399. PubMed ID: 27545217
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
5. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
6. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles.
Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H
Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871
[TBL] [Abstract][Full Text] [Related]
7. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of new boswellic acid derivatives as potential antiproliferative agents.
Shamraiz U; Hussain H; Ur Rehman N; Al-Shidhani S; Saeed A; Khan HY; Khan A; Fischer L; Csuk R; Badshah A; Al-Rawahi A; Hussain J; Al-Harrasi A
Nat Prod Res; 2020 Jul; 34(13):1845-1852. PubMed ID: 30691289
[TBL] [Abstract][Full Text] [Related]
9. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD
Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369
[TBL] [Abstract][Full Text] [Related]
10. Acetyl-11-keto-β-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway.
Sun MX; He XP; Huang PY; Qi Q; Sun WH; Liu GS; Hua J
World J Gastroenterol; 2020 Oct; 26(38):5822-5835. PubMed ID: 33132637
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-11-keto-β-boswellic acid (AKBA) inhibits human gastric carcinoma growth through modulation of the Wnt/β-catenin signaling pathway.
Zhang YS; Xie JZ; Zhong JL; Li YY; Wang RQ; Qin YZ; Lou HX; Gao ZH; Qu XJ
Biochim Biophys Acta; 2013 Jun; 1830(6):3604-15. PubMed ID: 23500016
[TBL] [Abstract][Full Text] [Related]
12. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
13. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
15. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
[TBL] [Abstract][Full Text] [Related]
16. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
[TBL] [Abstract][Full Text] [Related]
17. Acetyl-11-keto-β-boswellic acid triggers premature senescence via induction of DNA damage accompanied by impairment of DNA repair genes in hepatocellular carcinoma cells in vitro and in vivo.
Wang S; Wang H; Sun B; Li D; Wu J; Li J; Tian X; Qin C; Chang H; Liu Y
Fundam Clin Pharmacol; 2020 Feb; 34(1):65-76. PubMed ID: 31141202
[TBL] [Abstract][Full Text] [Related]
18. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
[TBL] [Abstract][Full Text] [Related]
19. 3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase.
Li W; Liu J; Fu W; Zheng X; Ren L; Liu S; Wang J; Ji T; Du G
J Exp Clin Cancer Res; 2018 Jul; 37(1):132. PubMed ID: 29970196
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
